34. Augmenting CNS Glucocerebrosidase Activity as a Therapeutic Strategy for Parkinsonism and Other Gaucher-Related Synucleinopathies

Molecular Therapy - United States
doi 10.1016/s1525-0016(16)34369-6
Full Text
Abstract

Available in full text

Date
Authors

Unknown

Publisher

Elsevier BV

Related search

Incidence and Pathology of Synucleinopathies and Tauopathies Related to Parkinsonism

JAMA Neurology
Neurology
2013English

Testing NMDA Receptor Block as a Therapeutic Strategy for Reducing Ischaemic Damage to CNS White Matter

GLIA
Molecular NeuroscienceNeurologyCellular
2007English

Glucocerebrosidase 2 Gene Deletion Rescues Type 1 Gaucher Disease

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2014English

High Throughput Screening for Small Molecule Therapy for Gaucher Disease Using Patient Tissue as the Source of Mutant Glucocerebrosidase

PLoS ONE
Multidisciplinary
2012English

RGS6 as a Novel Therapeutic Target in CNS Diseases and Cancer

AAPS Journal
Pharmaceutical Science
2016English

How Methotrexate Is Involved in the Therapeutic Strategy of CNS Sarcoidosis ?

The Japanese Journal of Sarcoidosis and Other Granulomatous Disorders
2014English

Gaucher Disease: Isolation and Comparison of Normal and Mutant Glucocerebrosidase From Human Spleen Tissue.

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
1978English

Development of Targeted Therapies for Parkinson’s Disease and Related Synucleinopathies

Journal of Lipid Research
BiochemistryEndocrinologyCell Biology
2014English

Evaluation of Quinazoline Analogues as Glucocerebrosidase Inhibitors With Chaperone Activity

Journal of Medicinal Chemistry
Drug DiscoveryMolecular Medicine
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy